Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=269 Effect of Medical Marijuana on Neurocognition and Escalation of Use
Pain · Insomnia · Depression
Primary: Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks — 0.39; 0.12 score on a scale — p=<0.001
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
N/A N=25 Impact of Reduced Cannabis Use on Functional Outcomes
Cannabis · Cannabis Use
Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Phase 4 N=175 Buspirone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS
Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Phase 2 N=76 Vilazodone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS
Phase 1 N=10 Marijuana Effects on Simulated Driving Performance
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
N/A N=107 Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco
Smoking Cessation · Marijuana Use
Primary: Number of Calls Completed — 123; 141 Total number of calls
Phase 2 N=14 Effects of Marijuana on Symptoms of OCD
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
N/A N=60 Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
Marijuana Use · Pregnancy
Primary: Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery — 6; 7; 6; 3 Participants
Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale
Phase 2 N=21 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Marijuana Abuse
Primary: Marijuana Use — 2.5; 3.9 Reported uses per day
N/A N=44 Reactions of Older Adults Driving After Cannabis Exposure
Chronic Pain
Primary: Simulated Driving Performance Task Measuring Divided Attention — 3.42; 2.57 units on a scale
N/A N=253 Pain Research: Innovative Strategies With Marijuana
Chronic Pain · Chronic Low Back Pain · Cannabis Use
Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale
Phase 2 N=157 Marijuana's Impact on Alcohol Motivation and Consumption
Alcohol Drinking · Marijuana
Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Early Phase 1 N=10 Influence of Edible Marijuana on Endurance Exercise Performance
Endurance Exercise
Primary: Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo. — 0.9699; 1.1437; 1.26345; 1.3618…
N/A N=60 Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)
Cannabis · Cannabis Use
Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 2 N=16 Baclofen Effects on Marijuana Dependence
Marijuana Dependence
Primary: Urine Drug Screen — 0; 0 Participants
N/A N=58 Hormones and Reduction in Co-users of Marijuana and Nicotine
Marijuana Dependence
Primary: Change in Marijuana Use as Defined by the TLFB — -1.7; -1.4; -0.9; -2.9 MJ use occasions per day
Phase 2 N=23 Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Marijuana Smoking
Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)
Early Phase 1 N=43 Brain Imaging of Cannabinoid Receptors
Cannabis Use Disorder · Cannabis Dependence, Continuous
Primary: Distribution Volume (VT) — 1.27; 1.54; 1.14; 1.31 mL/cm^3 — p=0.02
Phase 2 N=130 Quetiapine Pharmacotherapy for Cannabis Dependence
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars
N/A N=22 Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Multiple Sclerosis
Primary: Fatigue — 21; 24 % decline